Sandbox: prognosis: Difference between revisions
Jump to navigation
Jump to search
(Created page with "* The table below lists prognostic factors for chronic lymphocytic leukemia:<ref>Hoffbrand V, Moss P. Essential Haematology. John Wiley & Sons; 2011</ref> Gender Males are as...") |
No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 1: | Line 1: | ||
* The table below lists prognostic factors for chronic lymphocytic leukemia:<ref>Hoffbrand V, Moss P. Essential Haematology. John Wiley & Sons; 2011</ref> | * The table below lists prognostic factors for chronic lymphocytic leukemia:<ref name="pmid25461996">{{cite journal| author=Nabhan C, Rosen ST| title=Chronic lymphocytic leukemia: a clinical review. | journal=JAMA | year= 2014 | volume= 312 | issue= 21 | pages= 2265-76 | pmid=25461996 | doi=10.1001/jama.2014.14553 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25461996 }} </ref><ref>Hoffbrand V, Moss P. Essential Haematology. John Wiley & Sons; 2011</ref> | ||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" | {| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" | ||
Line 22: | Line 10: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Gender'''|| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Age'''|| style="padding: 5px 5px; background: #F5F5F5;" | | ||
:* Males are associated with a worse prognosis | :* Older age of diagnosis is associated with a worse prognosis. | ||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Gender'''|| style="padding: 5px 5px; background: #F5F5F5;"| | |||
:* Males are associated with a worse prognosis. | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Performance status'''|| style="padding: 5px 5px; background: #F5F5F5;"| | |||
:* Patient's poor performance status is associated with a worse prognosis. | |||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Stage'''|| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Stage'''|| style="padding: 5px 5px; background: #F5F5F5;" | | ||
:*Binet stages B and C or Rai stages II–IV are associated with a worse prognosis | :*Binet stages B and C or Rai stages II–IV are associated with a worse prognosis. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lymphocyte doubling time'''|| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lymphocyte doubling time'''|| style="padding: 5px 5px; background: #F5F5F5;" | | ||
:* | :*A rapid lymphocyte doubling time is associated with a worse prognosis | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Genetic mutations'''|| style="padding: 5px 5px; background: #F5F5F5;"| | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Genetic mutations'''|| style="padding: 5px 5px; background: #F5F5F5;"| | ||
:*Deletion of chromosome 17 short arm is associated with a worse prognosis | :*Deletion of chromosome 17 short arm is associated with a worse prognosis. | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Prolymphocytes percent'''|| style="padding: 5px 5px; background: #F5F5F5;" | | |||
:*An increased percentage of prolymphocytes is associated with a worse prongnosis. | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Histological analysis'''|| style="padding: 5px 5px; background: #F5F5F5;"| | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Histological analysis'''|| style="padding: 5px 5px; background: #F5F5F5;"| | ||
:*Diffuse histology on bone marrow aspiration is associated with a worse prognosis | :*Diffuse histology on bone marrow aspiration is associated with a worse prognosis. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lactate dehydrogenase (LDH) level'''|| style="padding: 5px 5px; background: #F5F5F5;"| | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lactate dehydrogenase (LDH) level'''|| style="padding: 5px 5px; background: #F5F5F5;"| | ||
:*Elevated levels of LDH | :*Elevated levels of LDH are associated with a worse prognosis. | ||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''β2-microglobulin level '''|| style="padding: 5px 5px; background: #F5F5F5;"| | |||
:*Elevated levels of β2-microglobulin level are associated with a worse prognosis. | |||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lymphocyte surface marker'''|| style="padding: 5px 5px; background: #F5F5F5;"| | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lymphocyte surface marker'''|| style="padding: 5px 5px; background: #F5F5F5;"| | ||
:*Positive expression of CD38 is associated with a worse prognosis | :*Positive expression of CD38 is associated with a worse prognosis. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Immunoglobulin (Ig)VH gene'''|| style="padding: 5px 5px; background: #F5F5F5;"| | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Immunoglobulin (Ig)VH gene'''|| style="padding: 5px 5px; background: #F5F5F5;"| | ||
:*The absence of VH gene mutation is associated with a worse prognosis | :*The absence of VH gene mutation is associated with a worse prognosis. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Membrane-bound proteins'''|| style="padding: 5px 5px; background: #F5F5F5;"| | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Membrane-bound proteins'''|| style="padding: 5px 5px; background: #F5F5F5;"| | ||
:*The expression of Zeta-chain-associated protein kinase 70 (ZAP)is associated with a poor prognosis | :*The expression of Zeta-chain-associated protein kinase 70 (ZAP) is associated with a poor prognosis. | ||
|} | |} |
Latest revision as of 00:04, 14 October 2015
Prognostic Factor | Description |
---|---|
Age |
|
Gender |
|
Performance status |
|
Stage |
|
Lymphocyte doubling time |
|
Genetic mutations |
|
Prolymphocytes percent |
|
Histological analysis |
|
Lactate dehydrogenase (LDH) level |
|
β2-microglobulin level |
|
Lymphocyte surface marker |
|
Immunoglobulin (Ig)VH gene |
|
Membrane-bound proteins |
|
- ↑ Nabhan C, Rosen ST (2014). "Chronic lymphocytic leukemia: a clinical review". JAMA. 312 (21): 2265–76. doi:10.1001/jama.2014.14553. PMID 25461996.
- ↑ Hoffbrand V, Moss P. Essential Haematology. John Wiley & Sons; 2011